ACTRN12614000060640已完成1 期
Study of the safety and tolerability of IV infused PG545 in patients with advanced solid tumours
Progen Pharmaceuticals Ltd0 个研究点目标入组 25 人开始时间: 2014年1月20日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Age 18 years and older.
- •- Histological or cytological documentation of non haematological, malignant solid tumour, excluding primary brain or spinal tumours.
- •- Subjects with advanced solid tumours who have failed all standard therapies, no longer are candidates for standard therapy, have no standard therapy available, or choose not to pursue standard therapy (the later is to be documented).
- •- Measurable disease (at least 1 target lesion) according to RECIST 1.1.
- •- Life expectancy of at least 12 weeks.
- •- ECOG Performance Status of 0 or 1.
- •- Written, signed and dated informed consent to participate in study.
- •- Able and willing to meet all protocol-required treatments, investigations and visits.
- •- Have adequate organ function including: Bone Marrow Reserve: Total white blood cell (WBC) count greater than or equal to 2300 cells/microL, absolute neutrophil count (ANC) greater than or equal to 1500 cells/microL, platelets greater than or equal to 100,000/microL, haemoglobin greater than or equal to 9 g/dL; Hepatic: Bilirubin less than or equal to 1.5 x upper limits of normal (ULN), alanine transaminase (ALT) and aspartate transaminase (AST) less than or equal to 2.5 x ULN – if liver metastases are present then less than or equal to 5 x ULN; Renal: serum creatinine less than or equal to 1.5 times ULN - subjects with a serum creatinine greater than 1.5 x ULN may be enrolled if their creatinine clearance is calculated or measured at greater than 60 mL/minute; Coagulation: Activated partial thromboplastin time (APTT) and prothrombin time (PT) less than or equal to 1.2 x ULN.
排除标准
- •- Clinically significant non-malignant disease including, but not limited to, major surgery within 6 weeks of randomisation, active clinically significant infection, myocardial infarction within 6 months prior to randomisation, cerebrovascular event or transient ischaemic attack within 12 months prior to randomisation or clinically significant gastrointestinal bleeding within 12 months prior to randomisation. Anti-cancer therapy within 4 weeks of Cycle 1 day 1 (excluding GnRH agonists for prostate cancer). Palliative radiation for bone metastases within 2 weeks of Cycle 1 day 1.
- •- Active CNS metastases. Subjects with prior CNS metastases treated by surgery and/or stereotactic irradiation are eligible providing they have no evidence of active disease at screening. Subjects with prior CNS metastases treated with only whole brain radiation therapy are ineligible.
- •- Subjects with uncontrolled diabetes.
- •- History of allergy and / or hypersensitivity and / or other clinically significant adverse drug reaction to heparin or other anti-coagulant agents.
- •- History of immune-mediated thrombocytopaenia or other platelet abnormalities or other hereditary or acquired coagulopathies, or laboratory evidence of anti-heparin antibodies, or any previous history of having tested positive for anti-heparin antibodies.
- •- Concomitant use of aspirin (> 150 mg/day), non steroidal anti-inflammatory drugs (except COX-2 selective inhibitors), vitamin K antagonists (other than low-dose prophylactic use), heparin within two weeks prior to randomisation, or other anti-platelet drugs (e.g. abciximab, clopidogrel, dipyridamole, ticlopidine and tirofiban). Low-dose aspirin (= 150 mg/day) and low dose prophylactic vitamin K antagonists (e.g. warfarin = 1 mg/day) are permitted as concomitant medications.
- •- History of severe allergic, anaphylactic or other significant adverse reaction to radiographic contrast media (iodinated or non-iodinated), which cannot be managed by pre treatment with agents such as steroids or anti histamines, and which, in the opinion of the Investigator, renders the subject unsuitable for routine CT or MRI scanning. Subjects who are contra-indicated for CT or MRI scanning for other reasons (e.g. ferromagnetic implants, profound claustrophobia), should not be enrolled.
- •- Known seropositivity to the human immunodeficiency virus (HIV).
- •- Women who are pregnant or breast-feeding.
- •- Women of child-bearing potential and male subjects who are partners of women of childbearing potential who are unable or unwilling to practice a highly effective means of contraception. Effective birth control includes: a) birth control pills, depot progesterone, or an intrauterine device plus one barrier method, or b) two barrier methods. Effective barrier methods are: male and female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm).
- •- Active substance abuse, including alcohol, which, in the opinion of the Investigator, risks impairing the ability of the subject to comply with the protocol.
- •- Subjects who have received an investigational agent within 28 days prior to Cycle 1 Day 1; or are currently participating in any other clinical study or research project which involves administration of a pharmaceutical product or experimental treatment, or which involves protocol-specified laboratory tests, imaging studies or other investigations.
研究者
相似试验
已完成
不适用
Assessment on safety of intravenously administered trastuzumab with 100 ml saline solution in HER2 positive breast cancerBreast cancerJPRN-UMIN000006710Shiga University of Medical Science30
已完成
不适用
Vaccination against prostate cancerProstate cancerCancerISRCTN14654848Ahvaz Jundishapur University of Medical Sciences30
进行中（未招募）
1 期
A phase I safety and tolerability study of infusing the autologous progeny of an adult CD34+ subset into patients with type I diabetes mellitus and a successful renal transplant. - Stem cell and diabetes studyDiabetes mellitus type 1 and succesful renal transplantMedDRA version: 9.1 Level: LLT Classification code 10012638 Term: Diabetes with renal manifestationsMedDRA version: 9.1 Level: LLT Classification code 10038533 Term: Renal transplantEUCTR2006-002328-40-GBImperial College London7
进行中（未招募）
1 期
Study with hzVSF-v13 in patients with COVID-19 pneumonia: a phase II, proof of concept, multicentre, randomized, parallel-group, double-blind, placebo-controlled studyModerate-to-severe COVID-19 pneumoniaMedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862EUCTR2020-003614-13-ITImmuneMed Inc.105
已完成
2 期
Evaluating the effects of intravenous immunoglobulin (IVIG) in COVID-19 patientsIRCT20151227025726N20Shahid Beheshti University of Medical Sciences80